AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30307466 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (FEC100 followed by docetaxel)
Number of subjects: 106
Study 26454185 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation (5 weekly sessions)
Number of subjects: 15
Study 26454185 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Number of subjects: 15
Study 26454185 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched, low BDI-II score)
Number of subjects: 15
Study 25391006 — intervention group
Group type: EXPERIMENTAL
Intervention: RBV for 4 weeks followed by combined therapy with peg‐IFN alpha‐2a + RBV for 48 weeks (n = 73)
Number of subjects: 103
Study 25391006 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy with peg‐IFN alpha‐2a + RBV for 48 weeks (n = 30)
Number of subjects: 103
Study 22544891 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg once daily plus tiotropium 18 μg once daily
Number of subjects: 2276
Study 22544891 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 μg once daily
Number of subjects: 2276
Study 20844613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 150 × 10^6 autologous bone marrow mononuclear cells
Number of subjects: 87
Study 20844613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 19157158 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear polarized near-infrared light (PL) irradiation
Number of subjects: 20
Study 19157158 — intervention group
Group type: COMPARATOR
Intervention: Placebo-irradiation
Number of subjects: 20
Study 16012273 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI antidepressants
Number of subjects: 323
Study 16012273 — intervention group
Group type: EXPERIMENTAL
Intervention: SNRI antidepressants
Number of subjects: 323
Study 12651759 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid tablets (Aminogran Food Supplement, UCB)
Number of subjects: 21
Study 12651759 — intervention group
Group type: COMPARATOR
Intervention: Usual protein substitute drinks
Number of subjects: 21
Study 12651759 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid tablets
Number of subjects: 21
Study 10820174 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 120 mg alone
Number of subjects: 12
Study 10820174 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 120 mg plus sulfisoxazole
Number of subjects: 12
Study 8700047 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Position Monitor (HPM)
Number of subjects: 211
Study 8700047 — intervention group
Group type: COMPARATOR
Intervention: Force Platform (FP)
Number of subjects: 211
Study 1519497 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCu375
Number of subjects: 1790
Study 1519497 — intervention group
Group type: EXPERIMENTAL
Intervention: MLAgCu250
Number of subjects: 1790
Study 1519497 — intervention group
Group type: COMPARATOR
Intervention: Nova-T
Number of subjects: 1790
Study 6151343 — intervention group
Group type: EXPERIMENTAL
Intervention: Prizidilol (200 mg X 2)
Number of subjects: 0
Study 6151343 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg and 50 mg)
Number of subjects: 0
Study 6151343 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg)
Number of subjects: 0
Study 6151343 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg X 2 and 50 mg X 2)
Number of subjects: 0
Study 6151343 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg)
Number of subjects: 0
Study 6151343 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg)
Number of subjects: 0
Study 6151343 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg)
Number of subjects: 0
Study 6151343 — intervention group
Group type: EXPERIMENTAL
Intervention: Prizidilol (400 mg)
Number of subjects: 0
Study 31866327 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (5 mg/kg daily for 9 months)
Number of subjects: 6485
Study 31866327 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin (10 mg/kg daily for 4 months)
Number of subjects: 6485
Study 31866327 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 6485
Study 31866327 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 6485
Study 31753004 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 17600
Study 31753004 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation intervention
Number of subjects: 17600
Study 31753004 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies for Safety and Wellbeing
Number of subjects: 17600
Study 31753004 — intervention group
Group type: COMPARATOR
Intervention: Usual provision (control)
Number of subjects: 17600
Study 28744111 — intervention group
Group type: EXPERIMENTAL
Intervention: HCSMP-NHR (health-coaching self-management program)
Number of subjects: 90
Study 26493075 — intervention group
Group type: COMPARATOR
Intervention: Neutral film
Number of subjects: 105
Study 26493075 — intervention group
Group type: EXPERIMENTAL
Intervention: Real trauma film
Number of subjects: 105
Study 26493075 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma 'reappraisal' film
Number of subjects: 105
Study 24846707 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training on pedicle screw placement in the ImmersiveTouch simulator
Number of subjects: 26
Study 24846707 — intervention group
Group type: COMPARATOR
Intervention: Traditional visual/verbal instruction (non-simulation)
Number of subjects: 26
Study 21730017 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-649868 (10-80 mg single dose)
Number of subjects: 103
Study 21730017 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-649868 (5-30 mg multiple repeat dose)
Number of subjects: 103
Study 21730017 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-649868 (evening dosing)
Number of subjects: 103
Study 21730017 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-649868
Number of subjects: 103
Study 18946429 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine alone (Group II)
Number of subjects: 60
Study 18946429 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone alone (Group I)
Number of subjects: 60
Study 18946429 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone and ketamine combination (Group III)
Number of subjects: 60
Study 17311602 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium 40 microg by inhalation (positive control)
Number of subjects: 24
Study 17311602 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral loperamide 4 mg
Number of subjects: 24
Study 15724344 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil
Number of subjects: 34
Study 15724344 — intervention group
Group type: COMPARATOR
Intervention: Mineral oil
Number of subjects: 34
Study 11294513 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel 1.25 g (0.75 mg E2)
Number of subjects: 0
Study 11294513 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel 2.5 g (1.5 mg E2)
Number of subjects: 0
Study 11294513 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel 0.625 g (0.375 mg E2)
Number of subjects: 0
Study 11294513 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol patch delivering 0.05 mg E2 per day
Number of subjects: 0
Study 9767555 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple drug immunosuppressive regimen including CsA, azathioprine and corticosteroids
Number of subjects: 50
Study 9767555 — intervention group
Group type: COMPARATOR
Intervention: Quadruple sequential combination of rabbit antithymocyte globulin (ATG) for 10 days, azathioprine, corticosteroids and delayed CsA
Number of subjects: 50
Study 9767555 — intervention group
Group type: COMPARATOR
Intervention: ATG group
Number of subjects: 50
Study 9767555 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple regimen group
Number of subjects: 50
Study 7874660 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital therapy alone
Number of subjects: 0
Study 7874660 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital therapy in combination with antidepressants
Number of subjects: 0
Study 3396702 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage testosterone enanthate (TE) for 5 to 6 months
Number of subjects: 11
Study 3396702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sesame oil) injections for 5 to 6 months
Number of subjects: 11
Study 30791735 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy (60 minutes once a week for 8 weeks)
Number of subjects: 58
Study 27723486 — intervention group
Group type: EXPERIMENTAL
Intervention: Video exposure to a snake in a single context
Number of subjects: 0
Study 27723486 — intervention group
Group type: EXPERIMENTAL
Intervention: Video exposure to a snake in multiple contexts
Number of subjects: 0
Study 27723486 — intervention group
Group type: COMPARATOR
Intervention: No exposure (control group)
Number of subjects: 0
Study 25640834 — intervention group
Group type: EXPERIMENTAL
Intervention: Elementary school-based universal preventive intervention
Number of subjects: 0
Study 25640834 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24060261 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic variables
Number of subjects: 396
Study 24060261 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis-specific demographics (type, medication use)
Number of subjects: 396
Study 24060261 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical health-related variables
Number of subjects: 396
Study 24060261 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis-specific symptoms
Number of subjects: 396
Study 24060261 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behaviors
Number of subjects: 396
Study 24060261 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological variables
Number of subjects: 396
Study 24060261 — intervention group
Group type: EXPERIMENTAL
Intervention: Final model including all variables
Number of subjects: 396
Study 24060261 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, less than a high school education, rheumatoid arthritis, greater arthritis duration, taking steroids, taking narcotics, greater pain, greater stiffness, greater depressive symptoms, lower arthritis self-efficacy
Number of subjects: 396
Study 24060261 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender, fibromyalgia, excellent/very good health
Number of subjects: 396
Study 21428240 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine film-coated tablet (test formulation)
Number of subjects: 46
Study 21428240 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine orodispersible tablet (test formulation)
Number of subjects: 46
Study 21428240 — intervention group
Group type: COMPARATOR
Intervention: Reference formulations (brand formulations)
Number of subjects: 46
Study 19270165 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses
Number of subjects: 179
Study 19270165 — intervention group
Group type: COMPARATOR
Intervention: Flat inserts
Number of subjects: 179
Study 19270165 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 179
Study 19270165 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy plus orthoses
Number of subjects: 179
Study 19270165 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 179
Study 16288447 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based art therapy (MBAT)
Number of subjects: 111
Study 16288447 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 111
Study 16009748 — intervention group
Group type: EXPERIMENTAL
Intervention: Go Sun Smart (GSS) program
Number of subjects: 26
Study 11963648 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidose formulation of fenofibrate (67 mg)
Number of subjects: 48
Study 11963648 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidose formulation of fenofibrate (200 mg)
Number of subjects: 48
Study 11963648 — intervention group
Group type: COMPARATOR
Intervention: Reference micronized formulation of fenofibrate (67 mg)
Number of subjects: 48
Study 11963648 — intervention group
Group type: COMPARATOR
Intervention: Reference micronized formulation of fenofibrate (200 mg)
Number of subjects: 48
Study 11963648 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 48
Study 9792152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, Methotrexate, and Vinblastine (CMV)
Number of subjects: 214
Study 9792152 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate and Vinblastine (MV)
Number of subjects: 214
Study 7623260 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue thickness > 1 mm
Number of subjects: 37
Study 7623260 — intervention group
Group type: COMPARATOR
Intervention: Tissue thickness <= 1 mm
Number of subjects: 37
Study 2541159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (6 mg/h)
Number of subjects: 20
Study 2541159 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH (0.55 U/h)
Number of subjects: 20
Study 2541159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2541159 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH (30 micrograms/h)
Number of subjects: 20
Study 1101375 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate/betamethasone phosphate
Number of subjects: 22
Study 1101375 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone acetate/betamethasone phosphate
Number of subjects: 22
Study 31561272 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG with EMD
Number of subjects: 41
Study 31561272 — intervention group
Group type: COMPARATOR
Intervention: CTG only
Number of subjects: 41
Study 30941975 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention for increasing awareness of prostate cancer (PCa)
Number of subjects: 407
Study 30941975 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about PCa treatment success
Number of subjects: 407
Study 30941975 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage in which PCa is most frequently detected
Number of subjects: 407
Study 30941975 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive prostate examination
Number of subjects: 407
Study 27874307 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-free injection device
Number of subjects: 52
Study 27874307 — intervention group
Group type: COMPARATOR
Intervention: Conventional needle and syringe
Number of subjects: 52
Study 25759378 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 1351
Study 25759378 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (control)
Number of subjects: 1351
Study 21947374 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spa therapy (mud packs and thermal baths) and rehabilitation (exercises in a thermal pool) for 10 sessions
Number of subjects: 30
Study 21947374 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 21692970 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT-A (Dysport) 40 units per site, total 400 units
Number of subjects: 153
Study 21692970 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 153
Study 19636051 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HCV replication (detectable HCV RNA)
Number of subjects: 559
Study 19636051 — intervention group
Group type: COMPARATOR
Intervention: No active HCV replication (undetectable HCV RNA)
Number of subjects: 559
Study 19636051 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HCV replication
Number of subjects: 559
Study 19636051 — intervention group
Group type: COMPARATOR
Intervention: No active HCV replication
Number of subjects: 559
Study 17542112 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron treatment (5 mg elemental iron as ferrous sulfate per kg of body weight)
Number of subjects: 134
Study 17542112 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron treatment (5 mg elemental iron as ferrous sulfate per kg of body weight)
Number of subjects: 134
Study 17542112 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly iron treatment (5 mg elemental iron as ferrous sulfate per kg of body weight)
Number of subjects: 134
Study 15381643 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (n=505)
Number of subjects: 1011
Study 15381643 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=506)
Number of subjects: 1011
Study 11585004 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (Remicade)
Number of subjects: 150000
Study 9169251 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin formulation
Number of subjects: 12
Study 9169251 — intervention group
Group type: COMPARATOR
Intervention: Plain paracetamol
Number of subjects: 12
Study 9169251 — intervention group
Group type: COMPARATOR
Intervention: Soluble paracetamol
Number of subjects: 12
Study 9169251 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 12
Study 8192173 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% podofilox self-administered twice daily for 3 consecutive days per week for 4 weeks (stage 1)
Number of subjects: 100
Study 8192173 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% podofilox self-administered once daily for 3 days per week for 8 weeks (stage 2)
Number of subjects: 100
Study 8192173 — intervention group
Group type: COMPARATOR
Intervention: Placebo (stage 2)
Number of subjects: 100
Study 3285883 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin‐clavulanic acid (1.2 g intravenous)
Number of subjects: 300
Study 3285883 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (1 g suppository)
Number of subjects: 300
Study 3285883 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin‐clavulanic acid
Number of subjects: 300
Study 3285883 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 300
Study 30276206 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Tooth Mousse Plus
Number of subjects: 70
Study 30276206 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro™ White Varnish
Number of subjects: 70
Study 30276206 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat® Varnish
Number of subjects: 70
Study 30276206 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Pro‐Relief™ dentifrice
Number of subjects: 70
Study 30276206 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine™
Number of subjects: 70
Study 28107101 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg orally three times daily for 28 days
Number of subjects: 90
Study 28107101 — intervention group
Group type: COMPARATOR
Intervention: Placebo 10 mg orally three times daily for 14 days followed by domperidone 10 mg orally three times daily for 14 days
Number of subjects: 90
Study 25742888 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg enalapril plus 0.8 mg FA (high‐FA group)
Number of subjects: 480
Study 25742888 — intervention group
Group type: COMPARATOR
Intervention: 10 mg enalapril (control group)
Number of subjects: 480
Study 25742888 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg enalapril plus 0.4 mg FA (low‐FA group)
Number of subjects: 480
Study 23004926 — intervention group
Group type: EXPERIMENTAL
Intervention: Methantheline bromide (MB) 50 mg three times daily
Number of subjects: 339
Study 23004926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study 21045183 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose helical computed tomography (CT)
Number of subjects: 0
Study 21045183 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 0
Study 18679709 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene stent
Number of subjects: 30
Study 18679709 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic hydromer-coated polyurethane stent
Number of subjects: 30
Study 17342883 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid supplementation (9 essential and 3 non‐essential amino acids)
Number of subjects: 0
Study 17342883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14628974 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (4-12 mg/day)
Number of subjects: 39
Study 14628974 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20 mg/day)
Number of subjects: 39
Study 10971659 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mg Sirdalud
Number of subjects: 185
Study 10971659 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-mg Sirdalud MR
Number of subjects: 185
Study 10971659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 8884967 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated 7 days per week fractionation schedule (arm A)
Number of subjects: 44
Study 8884967 — intervention group
Group type: COMPARATOR
Intervention: Conventional 5 days per week treatment (arm B)
Number of subjects: 44
Study 1571205 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone, 40 mg/m2, given every other day as a single morning dose
Number of subjects: 80
Study 1571205 — intervention group
Group type: COMPARATOR
Intervention: Lactose, 40 mg/m2, given every other day as a single morning dose (Control)
Number of subjects: 80
Study 1571205 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 80
Study 1571205 — intervention group
Group type: COMPARATOR
Intervention: Lactose (Control)
Number of subjects: 80
Study 3880781 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of dimethylsulfoxide (DMSO) solution
Number of subjects: 20
Study 3880781 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 20
Study 31165506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraurethral self‐retaining device (ISRD)
Number of subjects: 177
Study 30242322 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia After Pediatric Cardiac Arrest In‐Hospital (THAPCA‐IH) and Out‐of‐Hospital (THAPCA‐OH) trials
Number of subjects: 222
Study 30242322 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing including the Mullen Scales of Early Learning (Mullen) and Wechsler Abbreviated Scale of Intelligence (WASI)
Number of subjects: 222